Sign inCreate account

Report workspace tools

NCT05534035UNKNOWNanonymous

A Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated With Vaxzevria®

Sponsor

Source record

Everest Medicines (Singapore) Pte. Ltd.

Phase

Source record

PHASE3

Modality

AI-normalized

RNA therapy

Target

AI-normalized

PTX-COVID19-B, Vaxzevria®

Indication / condition

AI-normalized

SARS-CoV-2 Infection

Intervention

Source record

PTX-COVID19-B, Vaxzevria®

Source & freshness

Source record

NCT ID

NCT05534035

Original source

ClinicalTrials.gov

Source last updated

Sep 09, 2022

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05534035

Title

A Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated With Vaxzevria®

Sponsor

Everest Medicines (Singapore) Pte. Ltd.

Status

UNKNOWN

Phase

PHASE3

Condition raw

SARS-CoV-2 Infection

Condition normalized

SARS-CoV-2 Infection

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

PTX-COVID19-B, Vaxzevria®

Target normalized

PTX-COVID19-B, Vaxzevria®

Interventions

PTX-COVID19-B, Vaxzevria®

Public preview

Source record

This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated with Vaxzevria®.

This study will be a competitive enrollment process in all participating countries. Once the target number of subjects is reached, the enrollment in all participating countries in the particular phase will be stopped.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated With Vaxzevria®

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05534035

Status

UNKNOWN

Phase

PHASE3

Sponsor

Everest Medicines (Singapore) Pte. Ltd.

Executive brief

Investment-Ready Snapshot

This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated with Vaxzevria®. This study will be a competitive enrollment process in all participating countries. Once the target number of subjects is reached, the enrollment in all participating countries in the particular phase will be stopped.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 09, 2022
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05534035

Indication

SARS-CoV-2 Infection

Modality

RNA therapy

Target

PTX-COVID19-B, Vaxzevria®

Intervention

PTX-COVID19-B, Vaxzevria®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.